Interferon-alpha therapy within the first year after acute hepatitis C infection in hernodialysis patients: efficacy and tolerance

Interferon-alpha therapy within the first year after acute hepatitis C infection in hernodialysis patients: efficacy and tolerance

Autor Rocha, Cristina M. Autor UNIFESP Google Scholar
Perez, Renata M. Google Scholar
Narciso, Janaina L. Autor UNIFESP Google Scholar
Ferreira, Adalgisa P. Autor UNIFESP Google Scholar
Lemos, Lara B. Autor UNIFESP Google Scholar
Medina-Pestana, Jose O. Autor UNIFESP Google Scholar
Silva, Antonio Eduardo B. Autor UNIFESP Google Scholar
Ferraz, Maria Lucia G. Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Universidade Federal do Rio de Janeiro (UFRJ)
Resumo Background Interferon monotherapy significantly reduces the chronicity rate of acute hepatitis C in nonuremic patients. in this clinical study, we evaluated the efficacy and tolerance of interferon-alpha( therapy for acute hepatitis C in hemodialysis patients.Methods Patients with acute hepatitis C, established on the basis of seroconversion to anti-hepatitis C virus and the presence of hepatitis C virus RNA, received a low dose of interferon-alpha (3 MU three times per week) for 12 months or a high dose (5 MU three times per week, preceded by a daily induction dose) for 6 months. Response to treatment was defined as undetectable hepatitis C virus RNA at the end of treatment and sustained virological response was defined as persistent negative hepatitis C virus RNA 6 months after the end of treatment.Results Twenty-three patients were treated, 16 with a low dose of interferon-alpha and seven with a high dose. At the end of treatment, hepatitis C virus RNA was undetectable in 16/ 23 patients (70%). of these, 6/23 patients (26%) relapsed and 10/23 (43%) maintained a sustained virological response (38% in lower doses vs. 57% in higher doses). Treatment was well tolerated and only three patients discontinued therapy (13%).Conclusion Interferon-a within the first year after acute hepatitis C in hemodialysis patients was found to be safe and effective, inducing a sustained virological response in 43% of cases. This study supports the routine indication of acute hepatitis C treatment with interferon-alpha for hemodialysis patients, and higher doses administered for a shorter period of time should be tried according to the tolerance of the patients.
Assunto acute hepatitis C
end-stage renal disease
hernodialysis
hepatitis C
interferon
side effects
Idioma Inglês
Data 2007-02-01
Publicado em European Journal of Gastroenterology & Hepatology. Philadelphia: Lippincott Williams & Wilkins, v. 19, n. 2, p. 119-123, 2007.
ISSN 0954-691X (Sherpa/Romeo, fator de impacto)
Editor Lippincott Williams & Wilkins
Extensão 119-123
Fonte http://dx.doi.org/10.1097/01.meg.0000252626.73172.f3
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000254354700006
URI http://repositorio.unifesp.br/handle/11600/29505

Mostrar registro completo




Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)